Spots Global Cancer Trial Database for recurrent small lymphocytic lymphoma

Every month we try and update this database with for recurrent small lymphocytic lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)	NCT00947388	Recurrent Small... Refractory Chro... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ...	Bendamustine Hy... Alemtuzumab	18 Years -	Case Comprehensive Cancer Center
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	NCT04007029	CD19 Positive CD20 Positive Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Mantl... Recurrent Prima... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Mant... Refractory Prim... Refractory Smal...	Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Tocilizumab	18 Years - 70 Years	Jonsson Comprehensive Cancer Center
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT01886859	Recurrent B-Cel... Recurrent Chron... Recurrent Small... Refractory B-Ce... Refractory Chro... Refractory Smal...	Ibrutinib Lenalidomide	18 Years -	National Cancer Institute (NCI)
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00019708	Extranodal Marg... Nodal Marginal ... Non-Hodgkin Lym... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu...	tanespimycin	19 Years -	National Cancer Institute (NCI)
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	NCT00723099	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Myeloge... Chronic Phase C... Indolent Non-Ho... Lymphoma Mixed Phenotype... Myelodysplastic... Myeloproliferat... Recurrent Chron... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Plasm... Recurrent Small... Recurrent T-Cel... Refractory Chro... Refractory Chro... Refractory Foll... Refractory Hodg... Refractory Lymp... Refractory Mant... Refractory Smal... T-Cell Non-Hodg...	Allogeneic Hema... Cyclophosphamid... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ...	- 69 Years	Fred Hutchinson Cancer Center
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation	NCT00003056	Leukemia Lymphoma Graft Versus Ho...	cyclosporine cyclosporine an...	18 Years - 55 Years	Takeda
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer	NCT00546377	Leukemia Lymphoma	filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma	NCT00244946	Lymphoma	therapeutic aut... carmustine cytarabine etoposide melphalan peripheral bloo...	15 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Bone Marrow Transplantation in Treating Patients With Lymphoma	NCT00002829	Lymphoma	Recombinant Int... Cyclophosphamid... Etoposide Mesna Bone Marrow Tra... Radiation Thera...	15 Years - 60 Years	M.D. Anderson Cancer Center
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	NCT00538187	Adult Non-Hodgk... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small...	obatoclax mesyl... bortezomib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Beta Alethine in Treating Patients With Low-Grade Lymphoma	NCT00007839	Lymphoma	beta alethine	18 Years -	National Cancer Institute (NCI)
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00119392	B-cell Chronic ... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Waldenström Mac...	rituximab cyclosporine fludarabine pho... mycophenolate m... yttrium Y 90 ib... peripheral bloo... allogeneic hema... total-body irra...	18 Years -	Fred Hutchinson Cancer Center
Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	NCT00017381	Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Extranodal Marg... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Stage I Adult D... Stage I Adult D... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenström Mac...	rituximab cyclophosphamid... filgrastim yttrium Y 90 ib... peripheral bloo...	18 Years - 70 Years	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma	NCT00045513	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	University Health Network, Toronto
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	NCT01381692	Recurrent Folli... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Recurrent Walde... Refractory Foll... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal...	Bortezomib Dexamethasone Laboratory Biom... Quality-of-Life... Rituximab Temsirolimus	18 Years -	National Cancer Institute (NCI)
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT00265928	Lymphoma	bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti...	18 Years -	National Cancer Institute (NCI)
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	NCT00101244	Adult Grade III... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	ispinesib laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202	NCT00896662	Lymphoma Solid Tumor	immunologic tec... laboratory biom... pharmacological...	18 Years -	Vanderbilt-Ingram Cancer Center
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00005601	Lymphoma	rituximab cisplatin cytarabine dexamethasone sargramostim	18 Years -	Alliance for Clinical Trials in Oncology
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00007852	Lymphoma	rituximab carmustine cytarabine etoposide melphalan autologous hema...	19 Years -	University of Nebraska
Interferon Alfa-2b in Treating Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma	NCT00006039	Lymphoma Small Intestine...	pegylated inter...	18 Years -	Memorial Sloan Kettering Cancer Center
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	NCT04659044	Recurrent B-Cel... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory B-Ce... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Mant... Refractory Marg... Refractory Smal...	Polatuzumab Ved... Rituximab Rituximab and H... Venetoclax	18 Years -	Academic and Community Cancer Research United
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma	NCT00278161	Leukemia Lymphoma	Pegfilgrastim Rituximab Cyclophosphamid...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma	NCT00004192	Lymphoma Neutropenia	filgrastim pegfilgrastim cisplatin cytarabine etoposide methylprednisol...	18 Years - 120 Years	University of Nebraska
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers	NCT00003163	Lymphoma Multiple Myelom...	filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera...	18 Years -	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma	NCT00007865	Lymphoma	rituximab carboplatin etoposide ifosfamide	19 Years - 120 Years	University of Nebraska
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant	NCT02662296	Prolymphocytic ... Recurrent Chron... Recurrent Non-H... Recurrent Small...	Ibrutinib Idelalisib	18 Years -	Fred Hutchinson Cancer Center
Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma	NCT00002697	Lymphoma	filgrastim sargramostim carboplatin etoposide ifosfamide autologous bone... bone marrow abl... peripheral bloo... radiation thera...	18 Years - 65 Years	Memorial Sloan Kettering Cancer Center
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00244985	Lymphoma	rituximab pegylated lipos...	18 Years - 120 Years	Roswell Park Cancer Institute
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT00079378	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Small... Refractory Chro... Untreated Adult...	decitabine valproic acid pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma	NCT00026429	Leukemia Lymphoma	denileukin dift...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation	NCT00003143	Lymphoma	Amifostine DHAP	18 Years -	Jonsson Comprehensive Cancer Center
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma	NCT00082823	Cancer	ziv-aflibercept	18 Years - 120 Years	Regeneron Pharmaceuticals
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00002908	Leukemia Lymphoma	bryostatin 1 vincristine sul...	18 Years -	Barbara Ann Karmanos Cancer Institute
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT00735930	Anemia Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... Thrombocytopeni...	Alvocidib Hydro... Lenalidomide Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma	NCT00848328	Lymphoma	Rituximab Lenalidomide	18 Years -	University of California, Davis
Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma	NCT00003356	Lymphoma	aldesleukin rituximab	18 Years - 75 Years	University of Rochester
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	NCT00005626	Leukemia Lymphoma	Irinotecan	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	NCT00017472	Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Stage III Margi... Stage III Small... Stage IV Margin... Stage IV Small ...	apolizumab laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	NCT03479268	B-Cell Prolymph... Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Non-H... Recurrent Small... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Non-... Refractory Smal... Richter Syndrom...	Ibrutinib Laboratory Biom... Pevonedistat Pharmacokinetic... Pharmacological...	18 Years -	City of Hope Medical Center
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	NCT00005786	Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	arsenic trioxid... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer	NCT00248430	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom...	aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo...	18 Years - 69 Years	Fred Hutchinson Cancer Center
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	NCT00118170	Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Mult... Splenic Margina... Stage II Multip... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Multi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Waldenström Mac...	sorafenib tosyl... pharmacological...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome	NCT00002989	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	busulfan cyclophosphamid... idarubicin melphalan radiation thera...	16 Years - 60 Years	National Cancer Institute (NCI)
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00040950	Lymphoma	rituximab agatolimod sodi...	18 Years -	National Cancer Institute (NCI)
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00062296	Leukemia Lymphoma	rituximab epirubicin hydr...	18 Years -	Fox Chase Cancer Center
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma	NCT00691652	Lymphoma	rituximab clofarabine DNA methylation... gene expression... microarray anal... polymerase chai... high performanc... laboratory biom...	18 Years - 89 Years	OHSU Knight Cancer Institute
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	NCT01045928	Adult Non-Hodgk... Adult Grade III... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage I Adult B... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult I... Stage I Adult L... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Waldenstrom Mac...	lenalidomide rituximab polymerase chai... nucleic acid se... polymorphism an... flow cytometry laboratory biom...	18 Years -	Case Comprehensive Cancer Center
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	NCT02007044	Prolymphocytic ... Recurrent Chron... Recurrent Small...	Ibrutinib Quality-of-Life... Questionnaire A... Rituximab	18 Years -	M.D. Anderson Cancer Center
Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma	NCT00002510	Lymphoma	filgrastim cyclophosphamid... etoposide mesna peripheral bloo... radiation thera...	16 Years - 65 Years	Temple University
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	NCT00010192	B-cell Adult Ac... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ...	rituximab aldesleukin laboratory biom... pharmacological...	18 Years -	National Cancer Institute (NCI)
Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	NCT00002779	Lymphoma	fludarabine pho... octreotide acet...	18 Years -	Alliance for Clinical Trials in Oncology
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	NCT02281279	B-cell Adult Ac... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Refractory Hair... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac...	rituximab lenalidomide romidepsin laboratory biom...	18 Years -	Mayo Clinic
PS-341 in Treating Patients With Advanced Cancer	NCT00006362	Leukemia Lymphoma Multiple Myelom... Precancerous Co... Unspecified Adu...	bortezomib	18 Years -	Mayo Clinic
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy	NCT00003341	Anemia Leukemia Lymphoma Multiple Myelom...	epoetin alfa quality-of-life...	18 Years -	Memorial Sloan Kettering Cancer Center
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma	NCT00006252	Leukemia Lymphoma	fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt...	- 69 Years	Alliance for Clinical Trials in Oncology
Bone Marrow Transplantation in Treating Patients With Lymphoma	NCT00002829	Lymphoma	Recombinant Int... Cyclophosphamid... Etoposide Mesna Bone Marrow Tra... Radiation Thera...	15 Years - 60 Years	M.D. Anderson Cancer Center
Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00005592	Lymphoma	90-Y-ibritumoma... rituximab indium In 111 i...	18 Years -	University of Alabama at Birmingham
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma	NCT00002880	Lymphoma	Etoposide phosp...	-	Alliance for Clinical Trials in Oncology
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	NCT01008462	B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac...	Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	NCT00040950	Lymphoma	rituximab agatolimod sodi...	18 Years -	National Cancer Institute (NCI)
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer	NCT00003661	Graft Versus Ho... Leukemia Lymphoma Myelodysplastic... Neuroblastoma	anti-thymocyte ... busulfan cyclosporine melphalan methylprednisol... umbilical cord ... radiation thera...	- 54 Years	Roswell Park Cancer Institute
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma	NCT00551239	Leukemia Lymphoma	rituximab fludarabine pho... pixantrone dima...	18 Years - 120 Years	CTI BioPharma
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	NCT00980395	Lymphoma Mantle Cell Lym... Indolent Lympho... SLL	rituximab bortezomib cladribine	18 Years -	University of Arizona
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT02332980	Recurrent B-Cel... Recurrent Chron... Recurrent Extra... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Margi... Recurrent Nodal... Recurrent Small... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Chro... Refractory Extr... Refractory Foll... Refractory Lymp... Refractory Noda... Refractory Smal... Refractory Sple... Refractory Wald... Richter Syndrom... Waldenstrom Mac...	Ibrutinib Idelalisib Laboratory Biom... Pembrolizumab	18 Years -	Mayo Clinic
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia	NCT00019838	Leukemia Lymphoma	7-hydroxystauro... fludarabine pho...	18 Years -	National Cancer Institute (NCI)
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma	NCT00334438	Lymphoma	rituximab bortezomib yttrium Y 90 ib... Indium 111 ibri...	18 Years - 120 Years	UNC Lineberger Comprehensive Cancer Center
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers	NCT01240525	Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic...	CD4 DLI No DLI	18 Years - 69 Years	University College, London

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: